CAS 1431326-61-2

LSD1-IN-1

Description:

LSD1-IN-1, with the CAS number 1431326-61-2, is a small molecule inhibitor specifically designed to target lysine-specific demethylase 1 (LSD1), an enzyme involved in the regulation of gene expression through histone modification. This compound is characterized by its ability to selectively inhibit LSD1, which plays a crucial role in various biological processes, including development, differentiation, and cancer progression. The inhibition of LSD1 can lead to the reactivation of silenced genes, making LSD1-IN-1 a potential candidate for therapeutic applications in cancer treatment and other diseases associated with epigenetic dysregulation. The compound typically exhibits favorable pharmacokinetic properties, including good solubility and bioavailability, which are essential for its efficacy in biological systems. Additionally, LSD1-IN-1 is often evaluated in preclinical studies to assess its potency, selectivity, and safety profile, contributing to the understanding of its potential as a therapeutic agent in oncology and epigenetic research.

Formula: C₁₅H₂₄Cl₂N₂

Synonyms:

• ORY-1001
• ORY-1001(LSD1-IN-1)
• ORY-1001 (RG-6016) 2HCl
• LSD1-IN-1
• ORY-1001 trans and cis isomers
• LSD1-IN-1;ORY1001;ORY 1001
• rel-N1-[(1R,2S)-2-Phenylcyclopropyl]-1,4-cyclohexanediamine hydrochloride (1:2)
• CS-1530
• ORY-1001 2HCl salt
• rel-N1-[(1R,2S)-2-Phenylcyclopropyl]-1,4-cyclohexanediamine hydrochloride
• ORY-1001 (RG-6016)
• RG 6016;RG6016;RG-6016;ORY1001;ORY 1001

LSD1-IN-1

CAS: 1431326-61-2

Formula: C₁₅H₂₄Cl₂N₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 303.2705

Ref: IN-DA009CIW

ORY1001

CAS: 1431326-61-2

ORY1001

Purity: ≥98%

Molecular weight: 303.27g/mol

Ref: 54-BUP07565

ORY1001

CAS: 1431326-61-2

ORY1001: Oral LSD1/KDM1A inhibitor, highly selective, IC50 <20 nM.

Formula: C₁₅H₂₂N₂·2HCl

Purity: 99.85% - 99.96%

Color and Shape: Solid

Molecular weight: 303.27

Ref: TM-T6922

ORY-1001

CAS: 1431326-61-2

Ory-1001 is a monoclonal antibody that binds to the HL-60 leukemia cell surface protein CD22, which is a receptor for the B-cell growth factor. Ory-1001 inhibits the binding of this growth factor to its receptor, thereby inhibiting cell proliferation and migration. Ory-1001 has been shown to eradicate leukemic stem cells in vivo and inhibit tumor growth in vitro. The drug has also been shown to have cardioprotective properties, likely due to its ability to inhibit the production of cardiac growth factors.

Formula: C₁₅H₂₂N₂·2HCl

Purity: Min. 95%

Molecular weight: 230.35 g/mol

Ref: 3D-GHC32661